KOLINPHARMA® signs an agreement with ASTAREAL® AB for distribution in the Asian market

KOLINPHARMA® signs an important three-year agreement with the multinational ASTAREAL® AB for distribution of products in Mainland China, Hong Kong, Macau, and Taiwan.

 The agreement, based on the Cross Boarder Ecommerce Law which entered into force in 2019, also provides that Kolinpharma® and AstaReal® undertake to make all the investments necessary for the setup of the e-commerce platforms and social media according to a digital marketing plan and a long-term strategy defined between the management of Kolinpharma® and the local skills of the headquarters team of Shangai by AstaReal®.

Rita Paola Petrelli, President of KOLINPHARMA®, commented: “We are proud to have sealed this very important partnership with the Swedish multinational, crucial for Kolinpharma's internationalization process. This agreement will allow us to initiate significant commercial development in a market with great potential such as the Asian one, that in China was worth 114.4 bi...

KOLINPHARMA® signs an important three-year agreement with the multinational ASTAREAL® AB for distribution of products in Mainland China, Hong Kong, Macau, and Taiwan.

 The agreement, based on the Cross Boarder Ecommerce Law which entered into force in 2019, also provides that Kolinpharma® and AstaReal® undertake to make all the investments necessary for the setup of the e-commerce platforms and social media according to a digital marketing plan and a long-term strategy defined between the management of Kolinpharma® and the local skills of the headquarters team of Shangai by AstaReal®.

Rita Paola Petrelli, President of KOLINPHARMA®, commented: “We are proud to have sealed this very important partnership with the Swedish multinational, crucial for Kolinpharma's internationalization process. This agreement will allow us to initiate significant commercial development in a market with great potential such as the Asian one, that in China was worth 114.4 billion CNY in 2014 and is estimated will reach 328.2 billion CNY (47 billion euros) in 2023."